Polymorphisms in isoniazid and prothionamide resistance genes of the Mycobacterium tuberculosis complex

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 9, 2011, Pages 4408-4411

  Projahn, Michaela ^a   Köser, Claudio U ^b   Homolka, Susanne ^a   Summers, David K ^b   Archer, John A C ^c   Niemann, Stefan ^a  

^a RESEARCH CENTER BORSTEL   (Germany)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c KING ABDULLAH UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

ISONIAZID; PROTIONAMIDE;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL STRAIN; GENE MUTATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PHYLOGENY; PRIORITY JOURNAL; SEQUENCE ANALYSIS;

ANTITUBERCULAR AGENTS; BACTERIAL PROTEINS; DRUG RESISTANCE, BACTERIAL; ISONIAZID; MYCOBACTERIUM TUBERCULOSIS; POLYMORPHISM, GENETIC; PROTHIONAMIDE;

EID: 80051809873     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00555-11     Document Type: Article

References (39)

1. Alix, E., S. Godreuil, and A B Blanc-Potard. 2006. Identification of a Haarlem genotype-specific single nucleotide polymorphism in the mgtC virulence gene of Mycobacterium tuberculosis. J. Clin. Microbiol. 44:2093-2098. (Pubitemid 43902158)
2. Basso, L., R. Zheng, J. Musser, W J Jacobs, and J. Blanchard. 1998. Mechanisms of isoniazid resistance in Mycobacterium tuberculosis: Enzymatic characterization of enoyl reductase mutants identified in isoniazid-resistant clinical isolates. J. Infect. Dis. 178:769-775. (Pubitemid 28397225)
3. Benatar, S, and R. Upshur. 2010. Tuberculosis and poverty: What could (and should) be done? Int. J. Tuberc. Lung Dis. 14:1215-1221.
4. Boehme, C C, et al. 2010. Rapid molecular detection of tuberculosis and rifampin resistance. N. Engl. J. Med. 363:1005-1015.
5. Brossier, F., N. Veziris, C. Truffot-Pernot, V. Jarlier, and W. Sougakoff. 2011. Molecular investigation of resistance to the antituberculous drug ethionamide in multidrug-resistant clinical isolates of Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 55:355-360.
6. Comas, I., S. Homolka, S. Niemann, and S. Gagneux. 2009. Genotyping of genetically monomorphic bacteria: DNA sequencing in Mycobacterium tuberculosis highlights the limitations of current methodologies. PLoS One 4:e7815.
7. Cox, H., et al. 2008. Emergence of extensive drug resistance during treatment for multidrug-resistant tuberculosis. N. Engl. J. Med. 359:2398-2400.
8. De Jong, B., M. Antonio, and S. Gagneux. 2010. Mycobacterium africanum - review of an important cause of human tuberculosis in West Africa. PLoS Negl. Trop. Dis. 4:e744.
9. Farmer, P E, B. Nizeye, S. Stulac, and S. Keshavjee. 2006. Structural violence and clinical medicine. PLoS Med. 3:e449.
10. Feuerriegel, S., et al. 2010. Thr202Ala in thyA is a marker for the Latin American Mediterranean lineage of the Mycobacterium tuberculosis complex rather than para-aminosalicylic acid resistance. Antimicrob. Agents Chemother. 54:4794-4798.
11. Gagneux, S, and P M Small. 2007. Global phylogeography of Mycobacterium tuberculosis and implications for tuberculosis product development. Lancet Infect. Dis. 7:328-337. (Pubitemid 46590063)
12. Galagan, J., et al. 2010. TB database 2010: Overview and update. Tuberculosis (Edinb.). 90:225-235.
13. Global Alliance for TB Drug Development. 2010. InhA inhibitors (GlaxoSmithKline). http://www.tballiance.org/new/portfolio/html-portfolio-item. php?id=5. Accessed 27 December 2010.
14. Hershberg, R., et al. 2008. High functional diversity in Mycobacterium tuberculosis driven by genetic drift and human demography. PLoS Biol. 6:e311.
15. Homolka, S., C. Köser, J. Archer, S. Rüsch-Gerdes, and S. Niemann. 2009. Single-nucleotide polymorphisms in Rv2629 are specific for Mycobacterium tuberculosis genotypes Beijing and Ghana but not associated with rifampin resistance. J. Clin. Microbiol. 47:223-226.
16. Homolka, S., et al. 2010. Unequal distribution of resistance-conferring mutations among Mycobacterium tuberculosis and Mycobacterium africanum strains from Ghana. Int. J. Med. Microbiol. 300:489-495.
17. Homolka, S., et al. 2008. High genetic diversity among Mycobacterium tuberculosis complex strains from Sierra Leone. BMC Microbiol. 8:103.
18. Ioerger, T R, et al. 2010. The non-clonality of drug resistance in Beijing-genotype isolates of Mycobacterium tuberculosis from the Western Cape of South Africa. BMC Genomics 11:670.
19. Johnson, R., et al. 2006. Drug resistance in Mycobacterium tuberculosis. Curr. Issues Mol. Biol. 8:97-111.
20. Keshavjee, S, and P. Farmer. 2010. Time to put boots on the ground: Making universal access to MDR-TB treatment a reality. Int. J. Tuberc. Lung Dis. 14:1222-1225.
21. Köser, C., D. Summers, and J. Archer. 2010. Role of the dihydrofolate reductase DfrA (Rv2763c) in trimethoprim-sulfamethoxazole (co-trimoxazole) resistance in Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 54:4951-4952.
22. Köser, C U, D K Summers, and J A Archer. 2011. Comment on: Isoniazid and rifampicin resistance-associated mutations in Mycobacterium tuberculosis isolates from Yangon, Myanmar: Isoniazid and rifampicin resistance-associated mutations in Mycobacterium tuberculosis isolates from Yangon, MyanmarImplications for rapid molecular testing. J. Antimicrob. Chemother. 66:686-687.
23. Köser, C U, D K Summers, and J A Archer. 2011. Thr270Ile in embC (Rv3793) is not a marker for ethambutol resistance in the Mycobacterium tuberculosis complex. Antimicrob. Agents Chemother. 55:1825.
24. N'Guessan, K R, M. Dosso, E. Ekaza, J. Kouakou, and V. Jarlier. 2008. Molecular characterisation of isoniazid-resistant Mycobacterium tuberculosis isolated from new cases in Lagunes region (Côte d'Ivoire). Int. J. Antimicrob. Agents 31:498-500.
25. Niemann, S., et al. 2009. Genomic diversity among drug sensitive and multidrug resistant isolates of Mycobacterium tuberculosis with identical DNA fingerprints. PLoS One 4:e7407.
26. Parrish, N, and K. Carrol. 2008. Importance of improved TB diagnostics in addressing the extensively drug-resistant TB crisis. Future Microbiol. 3:405-413.
27. Rüsch-Gerdes, S., G E Pfyffer, M. Casal, M. Chadwick, and S. Siddiqi. 2006. Multicenter laboratory validation of the BACTEC MGIT 960 technique for testing susceptibilities of Mycobacterium tuberculosis to classical second-line drugs and newer antimicrobials. J. Clin. Microbiol. 44:688-692.
28. Schön, T., et al. 2011. Wild-type distributions of seven oral second-line drugs against Mycobacterium tuberculosis. Int. J. Tuberc. Lung Dis. 15:502-509.
29. Schürch, A C, et al. 2011. Mutations in the regulatory network underlie the recent clonal expansion of a dominant subclone of the Mycobacterium tuberculosis Beijing genotype. Infect. Genet. Evol. 11:587-597.
30. Van Rie, A., L. Page-Shipp, L. Scott, I. Sanne, and W. Stevens. 2010. Xpert MTB/RIF for point-of-care diagnosis of TB in high-HIV burden, resource-limited countries: Hype or hope? Expert Rev. Mol. Diagn. 10:937-946.
31. Van Soolingen, D., P. Hermans, P. De Haas, D. Soll, and J. Van Embden. 1991. Occurrence and stability of insertion sequences in Mycobacterium tuberculosis complex strains: Evaluation of an insertion sequence-dependent DNA polymorphism as a tool in the epidemiology of tuberculosis. J. Clin. Microbiol. 29:2578-2586.
32. Vilchèze, C., et al. 2008. Mycothiol biosynthesis is essential for ethionamide susceptibility in Mycobacterium tuberculosis. Mol. Microbiol. 69:1316-1329.
33. Vilchèze, C., et al. 31 May 2011. Novel inhibitors of InhA efficiently kill Mycobacterium tuberculosis under aerobic and anaerobic conditions. Antimicrob. Agents Chemother. doi:10.1128/AAC.00266-11.
34. Wang, F., et al. 2010. Mycobacterium tuberculosis dihydrofolate reductase is not a target relevant to the antitubercular activity of isoniazid. Antimicrob. Agents Chemother. 54:3776-3782.
35. Weniger, T., J. Krawczyk, P. Supply, S. Niemann, and D. Harmsen. 2010. MIRU-VNTRplus: A web tool for polyphasic genotyping of Mycobacterium tuberculosis complex bacteria. Nucleic Acids Res. 38(Suppl.):W326-W331.
36. Wirth, T., et al. 2008. Origin, spread and demography of the Mycobacterium tuberculosis complex. PLoS Pathog. 4:e1000160.
37. World Health Organization. 2010. Global tuberculosis control 2010, p. 71. WHO Press, Geneva, Switzerland.
38. Yew, W W, C. Lange, and C C Leung. 2011. Treatment of tuberculosis: Update 2010. Eur. Respir. J. 37:441-462.
39. Young, D B, M D Perkins, K. Duncan, and C E Barry. 2008. Confronting the scientific obstacles to global control of tuberculosis. J. Clin. Invest. 118:1255-1265. (Pubitemid 351500418)